KR20130043194A - 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과 - Google Patents

아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과 Download PDF

Info

Publication number
KR20130043194A
KR20130043194A KR1020137003810A KR20137003810A KR20130043194A KR 20130043194 A KR20130043194 A KR 20130043194A KR 1020137003810 A KR1020137003810 A KR 1020137003810A KR 20137003810 A KR20137003810 A KR 20137003810A KR 20130043194 A KR20130043194 A KR 20130043194A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
methoxyphenyl
fluorophenyl
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137003810A
Other languages
English (en)
Korean (ko)
Inventor
셍-츄 궈
궈-슝 이
리-지유 황
리-첸 츄
티엔-숭 우
종-더 웨이
징-궁 청
재-추 양
치-훙 황
멩-퉁 자이
Original Assignee
타이알엑스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타이알엑스, 아이엔씨. filed Critical 타이알엑스, 아이엔씨.
Publication of KR20130043194A publication Critical patent/KR20130043194A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137003810A 2010-07-15 2011-07-14 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과 Ceased KR20130043194A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36476010P 2010-07-15 2010-07-15
US61/364,760 2010-07-15
PCT/US2011/043985 WO2012009519A1 (en) 2010-07-15 2011-07-14 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177029236A Division KR101913194B1 (ko) 2010-07-15 2011-07-14 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과

Publications (1)

Publication Number Publication Date
KR20130043194A true KR20130043194A (ko) 2013-04-29

Family

ID=44533096

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137003810A Ceased KR20130043194A (ko) 2010-07-15 2011-07-14 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과
KR1020177029236A Active KR101913194B1 (ko) 2010-07-15 2011-07-14 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177029236A Active KR101913194B1 (ko) 2010-07-15 2011-07-14 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과

Country Status (11)

Country Link
US (1) US8524740B2 (https=)
EP (2) EP3112348A1 (https=)
JP (3) JP2013532634A (https=)
KR (2) KR20130043194A (https=)
CN (1) CN103347859B (https=)
AU (1) AU2011279118B2 (https=)
BR (1) BR112013000716B1 (https=)
CA (2) CA2805590C (https=)
RU (1) RU2584688C2 (https=)
TW (1) TWI499417B (https=)
WO (1) WO2012009519A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077109A (ko) * 2015-06-03 2019-07-02 타이알엑스, 아이엔씨. 혈관형성 의태의 저해제로서의 아릴-퀴놀린 유도체의 신규한 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150370707A1 (en) * 2014-06-24 2015-12-24 Qualcomm Incorporated Disunited shared-information and private-information caches
CN108911967A (zh) * 2018-08-03 2018-11-30 上海华堇生物技术有限责任公司 2,5–二甲氧基苯甲酰氯的制备方法
CN112358462B (zh) * 2020-11-10 2023-11-10 成都伊诺达博医药科技有限公司 一种胡椒环衍生物的合成方法
FI4426434T3 (fi) 2021-11-02 2025-11-24 Flare Therapeutics Inc Pparg:n käänteisagonisteja ja niiden käyttöjä
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
CN116789567B (zh) * 2023-05-18 2026-03-27 福建凯昕药业有限公司 抗血小板减少症药芦曲泊帕中间体及其制备方法
WO2025250630A1 (en) * 2024-05-31 2025-12-04 Tairx, Inc. A linker-payload, an antibody-drug conjugate made thereby and uses thereof
CN120695016B (zh) * 2025-08-29 2025-12-02 北京大学 一种二氢喹啉衍生物在制备预防或治疗脂肪肝产品中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002145A2 (en) 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
JPH0733743A (ja) * 1993-07-22 1995-02-03 Kyorin Pharmaceut Co Ltd ２−アリール−４−キノリノール誘導体
US5571822A (en) * 1994-09-30 1996-11-05 The University Of North Carolina At Chapel Hill Antitumor compounds
US6569870B1 (en) * 2000-09-25 2003-05-27 The University Of North Carolina At Chapel Hill Fluorinated quinolones as antimitotic and antitumor agents
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
US6916831B2 (en) * 2003-02-24 2005-07-12 The University Of North Carolina At Chapel Hill Flavone acetic acid analogs and methods of use thereof
US6897316B2 (en) * 2003-08-08 2005-05-24 China Medical University Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents
US8440692B2 (en) * 2006-12-07 2013-05-14 China Medical University Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077109A (ko) * 2015-06-03 2019-07-02 타이알엑스, 아이엔씨. 혈관형성 의태의 저해제로서의 아릴-퀴놀린 유도체의 신규한 용도

Also Published As

Publication number Publication date
KR20170118244A (ko) 2017-10-24
CA2805590C (en) 2017-05-16
JP6371741B2 (ja) 2018-08-08
EP3112348A1 (en) 2017-01-04
AU2011279118A1 (en) 2012-12-20
CA2805590A1 (en) 2012-01-19
JP2016028032A (ja) 2016-02-25
CA2963390C (en) 2020-02-11
US8524740B2 (en) 2013-09-03
WO2012009519A1 (en) 2012-01-19
TW201206439A (en) 2012-02-16
AU2011279118B2 (en) 2014-12-18
CN103347859B (zh) 2015-12-02
RU2013105151A (ru) 2014-08-20
KR101913194B1 (ko) 2018-10-31
EP2593435A1 (en) 2013-05-22
TWI499417B (zh) 2015-09-11
JP6457584B2 (ja) 2019-01-23
BR112013000716A2 (pt) 2019-10-01
EP2593435B1 (en) 2016-09-07
RU2584688C2 (ru) 2016-05-20
JP2013532634A (ja) 2013-08-19
US20120015908A1 (en) 2012-01-19
BR112013000716B1 (pt) 2021-10-05
JP2017206511A (ja) 2017-11-24
CA2963390A1 (en) 2012-01-19
CN103347859A (zh) 2013-10-09

Similar Documents

Publication Publication Date Title
KR101913194B1 (ko) 아릴 및 헤테로아릴-퀴놀린 유도체의 합성 및 이의 항암 효과
EP2253625B1 (en) Pyridazinones, the preparation and the use thereof
KR102159442B1 (ko) 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용
CZ205994A3 (en) Heterobicyclic compounds
CN102146081B (zh) 吲哚乙酸衍生物及其制备方法和应用
KR20150000901A (ko) 히스톤 탈아세틸효소(hdacs) 억제제
US9061994B1 (en) Materials and methods useful to induce vacuolization, cell death, or a combination thereof
KR101975299B1 (ko) 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
EP1541149A1 (en) Phosphodiesterase inhibitor
EP2214667A2 (en) Small molecule inhibitors of parp activity
US20110098304A1 (en) Small molecule inhibitors of PARP activity
CN102584679A (zh) 一类苯并咔唑酰胺类化合物、其制备方法和用途
CN106061948A (zh) 水溶性的4‑氮杂鬼臼毒素类似物
WO2018237140A1 (en) Topoisomerase inhibitors with antibacterial and antcancer activity
Jaipea et al. STRUCTURAL MODIFICATION OF PIPERINE FROM PIPER NIGRUM L.
KR20100097939A (ko) 신규 ｃｋ2 저해제 및 그의 제조 방법
JP2000290280A (ja) フェニルアゾール化合物、製造法及び抗高脂血症薬
WO2014179401A1 (en) 2-arylnaphthyridin-4-ones as potent antitumor agents targeting tumorigenic cell lines
KR20100097940A (ko) 신규 ｃｋ2 저해제 및 그의 제조 방법
JP2004035483A (ja) ベンジルアミン誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150921

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161128

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170531

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170531

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170125

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150921

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170911

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170727

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170531

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170125

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150921

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171012